

# **Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/AA339AA012E7EN.html>

Date: July 2022

Pages: 51

Price: US\$ 3,500.00 (Single User License)

ID: AA339AA012E7EN

## **Abstracts**

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

According to the recently published report 'Adrenocorticotrophic Hormone Receptor - Drugs In Development, 2022'; Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - The adrenocorticotrophic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.

The report 'Adrenocorticotrophic Hormone Receptor - Drugs In Development, 2022' outlays comprehensive information on the Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development,

mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I and Discovery stages are 1, 2 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders and Undisclosed which include indications Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Endocrine Gland Disorders, IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Pituitary ACTH Hypersecretion (Cushing Disease) and Unspecified.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)

The report reviews Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects

The report assesses Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and @Scope

## Contents

Introduction

Global Markets Direct Report Coverage

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Overview

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Companies Involved in Therapeutics Development

Crinetics Pharmaceuticals Inc

Ferring Pharmaceuticals Inc

Mallinckrodt Plc

OMass Therapeutics Limited

Upsher-Smith Laboratories LLC

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Drug Profiles

AMZ-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

corticotropin - Drug Profile

Product Description

Mechanism Of Action

History of Events

corticotropin - Drug Profile

Product Description

Mechanism Of Action

cosyntropin SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

CRN-04894 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MC2 - Drug Profile

Product Description

Mechanism Of Action

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Dormant Products

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Discontinued Products

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Product Development Milestones

Featured News & Press Releases

May 25, 2022: Crinetics Pharmaceuticals reports positive top-line results including strong adrenal suppression from CRN04894 phase 1 study multiple-ascending dose cohorts

May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference

Dec 02, 2021: Amzell and Amring Pharmaceuticals attending 2021 American Epilepsy Society Meeting in Chicago

Nov 19, 2021: Amzell in collaboration With Amring Pharmaceuticals announce their lead product has entered Phase III clinical trial in the U.S. for treatment of infantile epileptic disease

Nov 17, 2021: Options for those who suffer from rheumatoid arthritis as new research reflects the benefit of repository corticotropin injection (RCI) to Real-World Clinical Outcomes

Aug 10, 2021: Crinetics Pharmaceuticals' oral ACTH antagonist, CRN04894, demonstrates pharmacologic proof-of-concept with dose-dependent cortisol suppression in single ascending dose portion of phase 1 study

Jul 01, 2021: Mallinckrodt announces inclusion of Acthar Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) treatment guidelines for patients with pulmonary sarcoidosis

May 03, 2021: Mallinckrodt presents data evaluating Acthar Gel (Repository Corticotropin Injection) for the treatment of severe keratitis at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting

Feb 04, 2021: Crinetics Pharmaceuticals lead ACTH antagonist for congenital adrenal hyperplasia and Cushing's disease (CRN04894) advances into phase 1 study

Nov 16, 2020: AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease

Oct 20, 2020: City of Rockford \$10 billion lawsuit against pharmaceutical giant Mallinckrodt threatened by bankruptcy

Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)

Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)

Jun 01, 2020: Mallinckrodt will appeal District Court ruling in case involving ongoing Acthar medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)

Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in *Rheumatology and Therapy*

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Crinetics Pharmaceuticals Inc, 2022

Pipeline by Ferring Pharmaceuticals Inc, 2022

Pipeline by Mallinckrodt Plc, 2022

Pipeline by OMass Therapeutics Limited, 2022

Pipeline by Upsher-Smith Laboratories LLC, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/AA339AA012E7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA339AA012E7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970